parallel randomized trial

ELAD

Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)

Design

Randomized: 204
Start year: 2014
Treatment: 52 weeks, follow-up 56 weeks
Countries: United Kingdom (24 sites)
Sponsor: Imperial College London (mixed)
Eligibility: age 50 or older; MMSE 15 or higher; CDR global 0.5 to 2; no diabetes treatment

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Placebo Placebo	lifestyle: not reported	102	82
A2	Liraglutide 1.8 mg subcutaneous once daily Liraglutide 1.8 mg daily	lifestyle: not reported	102	72

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Placebo A1	Liraglutide 1.8 mg subcutaneous once daily A2	Whole trial ALL
age	mean (years)	72.5	70.6
age	sd (years)	7.0	8.4
female	n	39	42
female	percent	38	41
other adas cog13	mean (points)	31.9	31.6
other adas cog13	sd (points)	9.3	10.3
other adcs adl	mean (points)	66.1	66.5
other adcs adl	sd (points)	9.7	9.5
other cdr sb	mean (points)	3.6	3.7
other cdr sb	sd (points)	1.8	1.9
other mmse	mean (points)	23.4	23.7
other mmse	sd (points)	3.6	3.5
other non white	n			4

3 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

CDR-SB change (1 lines; O100A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52	A2 vs A1	md	-0.06 points		-0.57 to 0.44		not stated; modified itt; R0011033:Results

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events	17.6			18 /	not stated; randomized; R0011033:Results
	A2	events	6.9			7 /	not stated; randomized; R0011033:Results